Inclusion Body Myositis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Inclusion Body Myositis Pipeline Analysis report covers drugs of 3 companies currently in different phases of development. Inclusion Body Myositis (IBM) is one of the inflammatory muscle diseases which involve muscle inflammation and the inflammation of the associated tissues. This includes the blood vessels which supply blood to these muscles. The name, IBM originate from the clumps of the discarded cellular materials (referred to as “bodies”) which collect in the muscles as a result of the body’s own defense mechanism damaging the muscles in an autoimmune process. The IBM leads to the slow and progressive muscle weakness of the wrists, fingers, thighs and the foot. The cause of the disease and muscle degeneration is however not clear but research is being carried to increase the understanding and are also finding ways for the prevention and treatment as well.
The report provides Inclusion Body Myositis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are ORPHAZYME A/S, Kv1.3 Therapeutics and Milo Biotechnology.
Scope:
Inclusion Body Myositis Pipeline Analysis report covers drugs of 3 companies currently in different phases of development. Inclusion Body Myositis (IBM) is one of the inflammatory muscle diseases which involve muscle inflammation and the inflammation of the associated tissues. This includes the blood vessels which supply blood to these muscles. The name, IBM originate from the clumps of the discarded cellular materials (referred to as “bodies”) which collect in the muscles as a result of the body’s own defense mechanism damaging the muscles in an autoimmune process. The IBM leads to the slow and progressive muscle weakness of the wrists, fingers, thighs and the foot. The cause of the disease and muscle degeneration is however not clear but research is being carried to increase the understanding and are also finding ways for the prevention and treatment as well.
The report provides Inclusion Body Myositis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are ORPHAZYME A/S, Kv1.3 Therapeutics and Milo Biotechnology.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
- Drug Name
- Generic Name
- Synonyms
- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. ORPHAZYME A/S
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Kv1.3 Therapeutics
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Milo Biotechnology
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
List of Tables
List of Figures
Companies Mentioned
- ORPHAZYME A/S
- Kv1.3 Therapeutics
- Milo Biotechnology
Methodology
LOADING...
